We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
View All

Blog - Pharmaceutical Preparation

Sage Therapeutics Rejects Biogen's Takeover Offer
Sage Therapeutics Rejects Biogen's Takeover Offer
Jan 27, 2025
Eye 163

Sage Therapeutics declines a buyout offer from Biogen, deeming it undervalued. The company seeks alternative strategies for shareholder benefit.
FDA Approves Monthly Dosing for Alzheimer's Drug Leqembi
FDA Approves Monthly Dosing for Alzheimer's Drug Leqembi
Jan 27, 2025
Eye 188

FDA approves monthly dosing for Alzheimer's drug Leqembi, offering a more convenient option for patients after 18 months of bi-weekly infusions.
Novo Nordisk Stock Surges as New Weight Loss Drug Shows Promise
Novo Nordisk Stock Surges as New Weight Loss Drug Shows Promise
Jan 24, 2025
Eye 214

Novo Nordisk's stock rises as new weight loss drug, amycretin, shows up to 22% weight loss in trials, boosting investor confidence.
Bristol Myers Squibb's Cobenfy Revolutionizing Alzheimer's Treatment
Bristol Myers Squibb's Cobenfy Revolutionizing Alzheimer's Treatment
Jan 15, 2025
Eye 138

Bristol Myers Squibb introduces Cobenfy, a landmark drug aimed at treating Alzheimer's-related psychosis and agitation, potentially transforming patient care and economic prospects.
Biogen's Growth Strategy Focuses on New Launches Over Acquisitions
Biogen's Growth Strategy Focuses on New Launches Over Acquisitions
Jan 15, 2025
Eye 202

Biogen aims for revenue growth through new product launches by 2028, emphasizing Alzheimer's research over acquisitions, as shared by CEO Chris Viehbacher at the JP Morgan Healthcare Conference.
Eli Lilly Revises Sales Expectations for Key Drugs
Eli Lilly Revises Sales Expectations for Key Drugs
Jan 14, 2025
Eye 86

Eli Lilly revises sales forecasts for Zepbound and Mounjaro, citing slower growth. Future revenue predictions remain optimistic.
Johnson & Johnson Expands Neurological Disorder Portfolio with Intra-Cellular Acquisition
Johnson & Johnson Expands Neurological Disorder Portfolio with Intra-Cellular Acquisition
Jan 14, 2025
Eye 192

Johnson & Johnson enhances its neurological disorder treatment portfolio by acquiring Intra-Cellular Therapies for $14.6 billion, positioning it for future growth and competition with biosimilars.
Pfizer Intensifies Efforts in Obesity Drug Development
Pfizer Intensifies Efforts in Obesity Drug Development
Jan 13, 2025
Eye 93

Pfizer is accelerating the development of an experimental obesity drug, a strategic move that aligns with rising global demand for innovative chronic health treatments.
Eli Lilly Anticipates Approval for Innovative Weight Loss Pill
Eli Lilly Anticipates Approval for Innovative Weight Loss Pill
Jan 13, 2025
Eye 115

Eli Lilly is gearing up for approval of its new weight loss pill, orforglipron, projected for early 2024, offering a promising alternative to injectable options in the expanding weight loss market.
Eli Lilly Acquires Scorpion Therapeutics for $2.5 Billion
Eli Lilly Acquires Scorpion Therapeutics for $2.5 Billion
Jan 13, 2025
Eye 102

Eli Lilly's $2.5 billion acquisition of Scorpion Therapeutics marks a significant expansion in its oncology portfolio, reflecting a focus on innovative cancer therapies.
Healthcare Deals Set for a Resurgence in 2025
Healthcare Deals Set for a Resurgence in 2025
Jan 13, 2025
Eye 186

The healthcare sector anticipates a resurgence in M&A activity by 2025, bolstered by improved economic conditions and reduced regulatory hurdles.
Metsera Eyes Nasdaq Listing Amid Buoyant Market Conditions
Metsera Eyes Nasdaq Listing Amid Buoyant Market Conditions
Jan 12, 2025
Eye 619

Metsera aims to go public on Nasdaq, capitalizing on strong equity markets and growing demand for weight-loss solutions, backed by ARCH Venture Partners.
Show more